These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 32594504)
1. Letter To The Editor - Drug Eruption After Sustained Release Naltrexone Pellet Implantation. Ak S; Can Gürel Ş Turk Psikiyatri Derg; 2020; 31(2):146-147. PubMed ID: 32594504 [No Abstract] [Full Text] [Related]
2. Naltrexone-induced Nicolau syndrome masquerading as cutaneous abscess. Perli D; Martone C; Rapose A BMJ Case Rep; 2012 Dec; 2012():. PubMed ID: 23242099 [TBL] [Abstract][Full Text] [Related]
3. Long-acting depot formulations of naltrexone for heroin dependence: a review. Krupitsky EM; Blokhina EA Curr Opin Psychiatry; 2010 May; 23(3):210-4. PubMed ID: 20224403 [TBL] [Abstract][Full Text] [Related]
5. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Fishman M Addiction; 2008 Aug; 103(8):1399-401. PubMed ID: 18855831 [TBL] [Abstract][Full Text] [Related]
6. Adverse effects of subcutaneous, drug-releasing implants for the treatment of opioid drug addiction. Bal C; Rappersberger K; Posch C J Dtsch Dermatol Ges; 2017 Dec; 15(12):1232-1234. PubMed ID: 28841773 [No Abstract] [Full Text] [Related]
7. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Krupitsky E; Zvartau E; Blokhina E; Verbitskaya E; Wahlgren V; Tsoy-Podosenin M; Bushara N; Burakov A; Masalov D; Romanova T; Tyurina A; Palatkin V; Slavina T; Pecoraro A; Woody GE Arch Gen Psychiatry; 2012 Sep; 69(9):973-81. PubMed ID: 22945623 [TBL] [Abstract][Full Text] [Related]
8. Lichenoid drug eruption associated with bisoprolol transdermal patches. Asano A; Nakai K; Tsuruta D Contact Dermatitis; 2022 Feb; 86(2):139-141. PubMed ID: 34687067 [No Abstract] [Full Text] [Related]
14. Naltrexone: a review of existing sustained drug delivery systems and emerging nano-based systems. Goonoo N; Bhaw-Luximon A; Ujoodha R; Jhugroo A; Hulse GK; Jhurry D J Control Release; 2014 Jun; 183():154-66. PubMed ID: 24704710 [TBL] [Abstract][Full Text] [Related]
15. Hepatic safety of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. Mitchell MC; Memisoglu A; Silverman BL J Stud Alcohol Drugs; 2012 Nov; 73(6):991-7. PubMed ID: 23036218 [TBL] [Abstract][Full Text] [Related]
16. Unplanned admissions to two Sydney public hospitals after naltrexone implants. Little M; Murray LM Med J Aust; 2008 Oct; 189(8):469; author reply 470-1. PubMed ID: 19024885 [No Abstract] [Full Text] [Related]
18. Blame the counselling, not the implant. A response to Oliver, Horspool & Keen (2005). Kunøe N; Lobmaier P Addiction; 2005 Jul; 100(7):1027-8; author reply 1028-9. PubMed ID: 15955020 [No Abstract] [Full Text] [Related]
19. Unplanned admissions to two Sydney public hospitals after naltrexone implants. Lloyd-Jones DM Med J Aust; 2008 Oct; 189(8):468-9; author reply 470-1. PubMed ID: 18928445 [No Abstract] [Full Text] [Related]